nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Baseline use of antiarrhythmics in patients given adaptive servoventilation: SERVE-HF
|
Festic, Emir |
|
2017 |
5 |
1 |
p. e4- 1 p. |
artikel |
2 |
Baseline use of antiarrhythmics in patients given adaptive servoventilation: SERVE-HF—Authors' reply
|
Eulenburg, Christine |
|
2017 |
5 |
1 |
p. e5- 1 p. |
artikel |
3 |
2016 CHEST annual meeting
|
Akkermans, Rebecca |
|
2017 |
5 |
1 |
p. 12- 1 p. |
artikel |
4 |
Chronic obstructive pulmonary disease (COPD)
|
Feetham, Laura |
|
2017 |
5 |
1 |
p. 18-19 2 p. |
artikel |
5 |
Community-based management of COPD in Nepal
|
Gautam, Rupesh |
|
2017 |
5 |
1 |
p. e6- 1 p. |
artikel |
6 |
Compelling evidence for the efficacy of α1-antitrypsin augmentation treatment for α1-antitrypsin deficiency
|
Crystal, Ronald G |
|
2017 |
5 |
1 |
p. 7-8 2 p. |
artikel |
7 |
Corrections
|
|
|
2017 |
5 |
1 |
p. e7- 1 p. |
artikel |
8 |
Corrections
|
|
|
2017 |
5 |
1 |
p. e7- 1 p. |
artikel |
9 |
Dante Alighieri: evidence for sleep disorder-related cardiac autonomic dysfunctions
|
Perciaccante, Antonio |
|
2017 |
5 |
1 |
p. 21- 1 p. |
artikel |
10 |
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
|
Nathan, Steven D |
|
2017 |
5 |
1 |
p. 33-41 9 p. |
artikel |
11 |
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
|
Raghu, Ganesh |
|
2017 |
5 |
1 |
p. 22-32 11 p. |
artikel |
12 |
GOLD grades are revised in latest strategy update
|
Burki, Talha Khan |
|
2017 |
5 |
1 |
p. 11- 1 p. |
artikel |
13 |
Great expectations for simtuzumab in IPF fall short
|
Meyer, Keith C |
|
2017 |
5 |
1 |
p. 2-3 2 p. |
artikel |
14 |
Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
|
King, Christopher S |
|
2017 |
5 |
1 |
p. 72-84 13 p. |
artikel |
15 |
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)
|
McElvaney, Noel G |
|
2017 |
5 |
1 |
p. 51-60 10 p. |
artikel |
16 |
Long-term oxygen in COPD
|
Burki, Talha Khan |
|
2017 |
5 |
1 |
p. 13- 1 p. |
artikel |
17 |
Multidrug-resistant Mycobacterium abscessus threatens patients with cystic fibrosis
|
van Dorn, Aaron |
|
2017 |
5 |
1 |
p. 15- 1 p. |
artikel |
18 |
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open
|
Raghu, Ganesh |
|
2017 |
5 |
1 |
p. e1-e2 nvt p. |
artikel |
19 |
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open—Authors' reply
|
Behr, Jürgen |
|
2017 |
5 |
1 |
p. e3- 1 p. |
artikel |
20 |
Pirfenidone and mortality in idiopathic pulmonary fibrosis
|
Spagnolo, Paolo |
|
2017 |
5 |
1 |
p. 3-5 3 p. |
artikel |
21 |
Respiratory syncytial virus-induced paediatric ARDS: why we should unpack the syndrome
|
Bem, Reinout A |
|
2017 |
5 |
1 |
p. 9-10 2 p. |
artikel |
22 |
Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?
|
Drilon, Alexander |
|
2017 |
5 |
1 |
p. 5-6 2 p. |
artikel |
23 |
The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
|
Martinez, Fernando J |
|
2017 |
5 |
1 |
p. 61-71 11 p. |
artikel |
24 |
The respiratory landscape in China: a focus on air pollution
|
Ouyang, Yadan |
|
2017 |
5 |
1 |
p. 16-17 2 p. |
artikel |
25 |
47th Union World Conference on Lung Health
|
Akkermans, Rebecca |
|
2017 |
5 |
1 |
p. 14-15 2 p. |
artikel |
26 |
Tobacco harm reduction revisited: back to the future
|
The Lancet Respiratory Medicine, |
|
2017 |
5 |
1 |
p. 1- 1 p. |
artikel |
27 |
Tuberculosis: the plague and I
|
Morgan, Jules |
|
2017 |
5 |
1 |
p. 20- 1 p. |
artikel |
28 |
UK Government chokes on air pollution crisis
|
Tang, Paul Kiet |
|
2017 |
5 |
1 |
p. 13- 1 p. |
artikel |
29 |
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
|
Yoh, Kiyotaka |
|
2017 |
5 |
1 |
p. 42-50 9 p. |
artikel |